【导读】低利率、严监管新时代，业内共话资管行业高质量发展之路 中国基金报记者 张燕北 孙晓辉 我国资管业务历经数十载风雨，如今已步入高质量发展新阶段。截至2024年末，中国资管行业总体规模 已突破140万亿元，成为居民财富管理和资本市场资源配置的重要力量。然而，在低利率与监管政策持 续完善的当下，行业转型压力与机遇并存。新时代下如何破局，实现从"规模驱动"向"质量引领"的深刻 转型成为全行业的核心命题。 马炜：从国际金融危机后FSB金融稳定理事会的稳健薪酬原则和实施标准发轫，顶层设计层层推进，深 刻重塑全球金融监管立法格局。我国金融机构绩效考核在借鉴国际经验的同时，结合国情迭代升级，从 早期向银行、保险、资管机构扩散的1.0版本，迈向契合国务院、国家金融监管总局、证监会高质量发 展文件要求的长周期考核2.0时代，这不仅是监管逻辑的演进，更是金融行业迈向高质量发展新征程的 关键锚点。 杨晴翔：从长远布局来看，资管机构实现高质量发展，要从资产端和资金端同时发力。资产端要提升投 研能力，这是资管机构最核心的竞争力，并根据市场环境变化，不断优化、完善和迭代投研框架，通过 多元化策略提升组合收益。资金端要加强与渠道、客 ...

为给予更多优秀医疗美容技术公司、医疗机构、医疗美容医疗器械制造商及其他相关单位充分的时间准备和完 善申报材料，主办方 探美医界、思宇MedTech 现决定将 奖 项评选报名截止时间延期至 2025年5月26日 24:00 。 此次延期旨在为有意参选的各方提供更充裕的时间窗口，以便大家能够更全面、深入地展示自身在医疗美容医 疗器械领域的创新成果与卓越贡献，分享前沿经验，推动医美医疗技术的持续进步。 大会将汇聚来自全球医疗美容产业的临床专家、顶尖科学家、科技创新者、投资机构与政府监管部门，共 同探讨医美科技前沿动态、创新技术产业化路径、政策监管趋势以及市场新机遇。 举办时间： 2025年6月12日星期四 举办地点： 北京中关村展示中心 会议规模： 现场500人 参会对象： 涵盖政府、医院、医美上下游企业、投资机构等综合性高知人士 大会议程要点（拟） 为表彰医疗美容科技领域内的卓越贡献，思宇MedTech及旗下专业媒体将组织评选2025全球医美科技创 新系列奖项，并于大会开幕式现场颁发。 全球医美产业趋势与市场洞察 医美新材料、新设备、新技术 再生医学、生物刺激等技术前沿 AI赋能、数字医美与个性化治疗 监管政策与 ...

Core Insights - The 12th Fortune Forum focused on new models of active equity investment in the A-share market, emphasizing consumer dynamics and the resilience of the Hong Kong stock market [1] - Key speakers provided forward-looking insights on investment strategies, industry allocation, and market positioning to instill confidence and vitality in the market [1] Group 1: A-share Market Insights - The A-share market is transitioning from a "stock economy" to a "new model," with Q1 2025 marking a turnaround in profit growth after four years of decline [2] - The core drivers of this reversal include low inventory levels triggering a replenishment cycle, companies operating with less burden, and a recovery in the real estate chain due to a rebound in second-hand housing [2] - Return on Equity (ROE) has significantly improved from its bottom, supported by a decrease in expense ratios offsetting operational pressures, and a recovery in asset turnover and leverage [2] - The market sentiment is expected to improve significantly due to the narrative of China's industrial transformation, including breakthroughs in AI and high-end manufacturing [2] Group 2: Consumer Sector Opportunities - The consumer sector is showing structural investment opportunities, with current price-to-earnings (PE) ratios at near ten-year lows and institutional holdings at a bottom [3] - Catalysts for a rebound in the consumer sector include a peak in household savings rates, improved income expectations, and the re-emergence of wealth effects [3] - Investment opportunities include traditional consumer leaders with stable dividends and new consumption trends such as domestic brand growth and service consumption upgrades [3] - The second half of 2025 may present a recovery window for the consumer sector due to supportive consumption policies and a favorable profit base effect [3] Group 3: Hong Kong Market Resilience - Despite facing foreign capital outflow pressures, the Hong Kong stock market shows resilience supported by continuous inflows from southbound funds and increased company buybacks [4] - The Hang Seng Index has achieved a 12% annualized return in RMB terms over the past three years, highlighting the market's value proposition [4] - A GARP (Growth at a Reasonable Price) strategy is recommended, focusing on high-growth sectors like consumer and technology, stable cash flow assets, and companies with low leverage and high governance standards [4][5] Group 4: Long-term Investment Strategy - The company emphasizes a fundamental approach to investment, selecting stocks based on strong earnings and favorable market conditions to achieve sustainable long-term returns [5] - The company has achieved a cumulative return of 953.86% over nearly two decades for its active equity products, positioning itself among industry leaders [5] - Continuous enhancement of professional investment capabilities is crucial for capturing certainty in investment opportunities amid global changes [5]

专题：第十二届富国论坛：AI驱动下的中国资产价值跃迁 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2025年5月23日上午，第十二届富国论坛——主动权益投资分论坛在苏州隆重召开。富国基金权益研究 部总经理陈杰、富国消费精选30基金经理周文波、富国基金海外权益投资部总经理张峰三位重量级嘉宾 受邀出席，共同探讨A股投资"新模式"、消费动能转换与港股市场韧性等核心议题，三位嘉宾从策略框 架、行业配置与市场布局角度，为投资者提供前瞻性主动权益投资指引，为市场注入信心与活力。 富国基金海外权益投资部总经理张峰在《港股投资，如何防守反击》报告中指出，尽管港股面临外资流 出压力，但南向资金持续流入与上市公司回购加码为市场提供韧性支撑。恒生指数近三年人民币计价年 化收益率达12%，AH溢价指数升至134，港股性价比凸显。 陈杰强调，"新模式"下ROE底部已显著抬升。尽管毛利率承压，但企业通过费用率下降对冲经营压力， 资产周转率与杠杆率触底回升，运营能力结构性改善为ROE修复提供支撑。此外，风险偏好自2024年四 季度见顶回落，叠加中国产业转型"突围"的大故事，如AI研发与高端制造双突破、产业集群 ...

消息面上，在创新治疗领域，中国企业的国际合作一直在持续。此前，百利天恒将双抗AD授权给百时 美施贵宝，以84亿美元的金额刷新了中国ADC新药"出海"的交易金额纪录。而刚实现"A+H"两地上市的 恒瑞医药近年来的BD更是进展迅速。截至目前，恒瑞医药已经实现14笔创新药License-out（对外授 权），其中近三年对外授权9笔，合作方包括默克、默沙东等国际巨头，涉及GLP-1、ADC等热门领 域。2024年中国创新药对License-out完成94笔，出海交易总金额高达519亿美元，同比增长26%。 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 中信建投证券认为，创新药板块近年来展现出强劲的技术驱动发展势头，尤其在抗体偶联药物 （ADC）、双特异性抗体（双抗）以及小分子疗法等领域取得了显著进展。以2025年美国临床肿瘤学 会（ASCO）年会为例，中国创新药企在此次会议上提交了超过70项口头报告，其中Late Breaking Abstra ...

消息面上，2025年5月23日，中国医药行业的领军企业恒瑞医药正式在港交所挂牌上市。此次全球发 售，恒瑞医药将获得募集资金净额约98.9亿港元。对于这笔巨额资金的用途，恒瑞医药有着明确的规 划：约75%将用于研发计划，约15%用于在中国和海外市场建设新的生产和研发设施，以及扩大或升级 现有生产和研发设施，约10%用作营运资金及其他一般企业用途。这不仅标志着恒瑞医药发展历程中的 又一重大跨越，上市首日超27%的涨幅也体现了资金对港股创新药板块的关注和认可。 港股创新药板块高盈利持续消化估值。港股创新药指数2月21日市盈率为64倍，5月23日最新市盈率仅为 27倍，不足两个月前的一半，当前布局性价比突出。 中航证券认为，国产创新药板块展现出显著的投资价值。在创新药企业出海持续推进的背景下，国内创 新药行业正经历深刻变化，企业核心优势不断叠加，持续强化自身竞争力，逐步从创新追随者转变为国 际竞争中的重要力量，并从国内市场走向国际舞台。近年来，国内创新药研发呈现快速发展态势，截至 2024年12月31日，中国企业研发的活跃状态创新药数量累计已达3575个，超越美国成为全球首位。从临 床试验的数目来看，2015-202 ...

Group 1 - The core viewpoint of the news highlights the approval of a new innovative drug by Heng Rui Medicine, which is the first self-developed DPP-4 inhibitor combined with metformin in China, aimed at improving blood sugar control for adult patients with type 2 diabetes [1] - Following the announcement, Heng Rui Medicine's stock surged nearly 30% in the Hong Kong market, indicating strong investor confidence in the innovative drug sector [1] - The Hong Kong innovative drug index has seen a significant decrease in its price-to-earnings ratio from 64 times on February 21 to 25 times on May 22, suggesting a favorable investment opportunity in the sector [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the National Index for Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends such as AI-enabled drug development and the expansion of domestic innovative drugs [2] - The larger innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from advancements in AI, the internationalization of domestic innovative drugs, and the introduction of new healthcare policies [2] - According to Xingye Securities, the innovative drug sector in China is transitioning from a "follower" to a "leader," with significant advancements expected in new targets and technologies by 2025, showcasing strong global competitiveness in areas like ADC, bispecific antibodies, and cell therapy [2]

Group 1 - The 21st China (Shenzhen) International Cultural Industries Fair was held from May 22 to May 26, showcasing the highest specifications and largest scale in the cultural industry sector in China [1] - Chengdu Media Group and Chengdu Media Industry Group represented the "Cultural Creative Army of Sichuan" at the fair, highlighting their innovative cultural and technological integration [1][6] - The exhibition featured four main sections: key cultural creative parks, cultural + technology demonstrations, cultural export initiatives, and cultural peripheral products, collectively promoting the "Chengdu Smart Media" concept globally [1][6] Group 2 - Significant projects displayed included the Dongjiao Memory International Fashion Industry Park, Chengdu International Intangible Cultural Heritage Expo Park, Chengdu Smart Media City, and the Bai Lu Bay Innovation Park, among others [6][9] - The event also showcased cultural initiatives such as the Panda Home Cultural Creative Competition and the upcoming 2025 Bahrain Silk Road Panda Lantern Carnival [6] - The fair highlighted AI-enabled media ecosystems, including a dedicated AI television platform and solutions for monitoring student mental development, emphasizing Chengdu's cultural depth and industrial vitality [9]

小而美、高弹性：港股创新药ETF（159567）跟踪国证港股通创新药指数，创新药企业权重90%为全市 场医药主题类指数中最高，有望把握AI赋能创新药研发、国产创新药出海、商业健康保险逐步完善的 创新药利好浪潮。 欧美市场的高支付能力与创新药的溢价空间，构成国产创新药出海的直接动力。以百济神州的泽布替尼 为例，其美国定价约6.3万元/瓶，而国内医保定价仅为1912元/瓶，中美售价相差超30倍。2025年一季 度，泽布替尼在美国销售额达5.63亿美元，同比增长60%，印证了"闯关欧美发达市场=手握全球通行 证"的商业逻辑。 港股创新药板块高盈利持续消化估值。港股创新药指数2月21日市盈率为64倍，5月22日最新市盈率仅为 25倍，不足两个月前的一半，当前布局性价比突出。 5月22日，港股市场低开震荡，港股创新药板块开盘下跌后快速反弹。港股创新药指数成分股中，金斯 瑞生物科技涨超5%，远大医药、亚盛医药-B、荣昌生物涨超3%，东阳光长江药业、中国生物制药涨超 1%。港股创新药ETF（159567）过去10个交易日资金净流入2.5亿元，市场热度较高。 广发证券认为，港股创新药板块作为具备全球竞争力的产业之一，其出海进 ...

战略转型成效显现，多业务协同发展 5月21日，宝尊电商（NASDAQ:BZUN，HK:9991）发布2025年第一季度财报。数据显示，公司一季度 净收入达21亿元，同比增长4%，其中电商板块收入企稳，品牌管理业务收入同比大增23%，非公认会 计准则下该业务经营亏损收窄28%，运营效率显著提升。 品牌管理业务：GAP逆势增长，本土化策略见效 品牌管理业务收入同比高增23%，主要由GAP中国同店销售增长、Hunter超预期表现驱动。尽管市场环 境承压，GAP同店销售额逆势增长5%，印证本土化运营能力突破。 渠道端，GAP持续优化门店网络，本季度关闭4家低效门店，单店坪效同比双位数增长；超40家新店完 成选址，10家将于Q2开业。通过精细化产品矩阵、灵活定价及店铺体验升级，客流与转化率双提升。 宝尊电商创始人、董事长兼CEO仇文彬指出，本季度战略转型扎实推进，营收结构多元化与各业务卓越 运营同步落地。电商板块在高质量发展中实现突破，品牌管理板块的GAP与Hunter超预期表现，进一步 坚定了公司对战略方向的信心。恰逢宝尊成立18周年，公司将以"成年礼"为新起点，加速构建数字化商 业平台。 电商业务：品类优化驱动增长 ...